Stellar Phase II data has helped Pfizer's breakthrough-designated meningitis B candidate surge ahead on its regulatory pathway to catch up with Novartis' Bexsero. And now, with the two companies submitting applications for approval on the same day, whether Pfizer's jab reaches the market first will be up to the FDA to decide.
Both Pfizer and Novartis have picked up the FDA's much-coveted breakthrough-therapy designation for their meningitis B vaccines, and now the rivals have chosen the same day to submit their injections for approval, leaving it up to regulators which will hit the market first.
With Pfizer's unwanted buyout bid in the past--at least for now--AstraZeneca needs to cheer up some of its shareholders. After all, some top investors in the U.K.-based drugmaker wanted to cash in on the proposed takeover. So, once again, CEO Pascal Soriot is making his case for AstraZeneca's bright future.
When Sanofi bought Genzyme, the deal was clinched on a contingent value right (CVR) based on the potential multiple sclerosis treatment Lemtrada. Could Pfizer do the same thing to win over AstraZeneca?
With AstraZeneca's CFO telling investors that Pfizer's colossal takeover bid failed purely because it was too cheap, creative dealmakers are looking at new ways to get the two parties shaking hands.
X-Chem has notched up some notable achievements in its first few years, including investment by CRO PPD, deals with AstraZeneca and Roche and the growth of its compound library to 100 billion small molecules. Now it has added another to the list by striking a drug discovery deal with Pfizer.
Want to know why the potential Pfizer-AstraZeneca marriage failed? Price, says Pfizer CFO Frank D'Amelio. Stating the obvious, obviously. But in balking at Pfizer's offer, AstraZeneca--and allies in the U.K.--raised plenty of other issues. Emotional issues, for some.
Several top AstraZeneca shareholders are pressing for meetings with John Varley, the former CEO of Barclays bank who also happens to head up the drugmaker's remuneration committee, Sky News reports. The aim? To follow through on calls to link AstraZeneca executive pay to the value of Pfizer's rejected buyout offer.
AstraZeneca's executive team under CEO Pascal Soriot confidently batted down Pfizer's $120 billion takeover bid by putting an extraordinary valuation on its pipeline, often far exceeding the most optimistic forecasts by industry analysts. And now there appears to be a growing movement among a group of disenchanted investors at the U.K. company to hold management's incentive packages hostage to the sky-high expectations they've created.
Lawsuits have been piling up against Abbott Laboratories and its recent spinoff, AbbVie, maker of one of the top-selling testosterone supplements, AndroGel. A panel of judges has now decided that those suits will be consolidated in Chicago, where both companies are based.